Suggested treatment algorithm for resistant lupus nephritis

Slides:

Advertisements

Similar presentations

Proteinuria Outcome Lupus Nephritis Classes of Lupus Nephritis I.Minimal II.Mesangial III.Focal proliferative* IV.Diffuse proliferative* V.Membranous**

Advertisements

“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.

Effects of MMF treatment in patients with SLE

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Relationship between urinary TNF-α and RANTES excretion

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Nat. Rev. Nephrol. doi: /nrneph

Membranous nephropathy: When and how to treat

Mycophenolate mofetil treatment for primary glomerular diseases

David J. Tunnicliffe, Suetonia C. Palmer

Nat. Rev. Rheumatol. doi: /nrrheum

Fnu Nutan, Alex G. Ortega-Loayza

Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer,

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Pharmacokinetics of mycophenolic acid in severe lupus nephritis

Volume 79, Issue 8, Pages (April 2011)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Immunosuppression in liver transplant recipients with renal impairment

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Proteinuria and hypertensive nephrosclerosis in African Americans

Association of the membrane-bound TLR to activity of LN. A.

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Seven-year cumulative incidence of ESRD according to baseline creatinine clearance (Ccr) and result of urine test for proteinuria (19). Seven-year cumulative.

Causal diagram showing assumed associations between baseline smoking status, ESRD, and baseline characteristics in the Study of Heart and Renal Protection.

Correlation between the difference in overnight pKt/V (A) or pCrCl (B) and the change in AHI following conversion from NPD to CAPD. pKt/V, peritoneal Kt/V;

Mean and median systolic and diastolic BPs after dialysis were unchanged over time and similar between epoetin alfa-epbx and epoetin alfa. Mean and median.

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.

Immunosuppression significantly reduced all-cause mortality or risk of ESRD (A) and significantly increased complete or partial remission (B) at the end.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Ratio of actual to expected rise in sodium as calculated using the Adrogué-Madias formula. Ratio of actual to expected rise in sodium as calculated using.

Ca2+ infusion rates during all three protocol versions.

Change in urinary protein to creatinine ratio (uPCR) as a function of serum C4, C3, anti-C1q, EC4d, EC3d and ECR1. Change in urinary protein to creatinine.

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Summary of evidence search and selection.

Six-month change in proteinuria predicts risk for ESRD

The same daily dose of metformin administered as different dosage regimens has differing effects on the concentration–time profile in a patient with CKD.

Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

We identified 200 Android and 178 iOS apps using 4 search terms and narrowed this to 12 Android apps, 11 iOS apps, and 5 dual-platform apps after applying.

Current standard of care treatment protocols for LN induction therapy.

Relationship between excess fluid, as determined by the difference between measured and estimated body water, and plasma albumin (R = −0.40, P = 0.011).

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

Association between hyperphosphatemia (serum phosphorus ≥4

Distribution of percent consistent facility aspirin use.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Bias with estimated GFR (eGFR) by age (years).

Per dialysis treatment funding and facility/network staff ratio by ESRD Network. Per dialysis treatment funding and facility/network staff ratio by ESRD.

Analysis of secreted proteins in the discovery panel.

Causal diagrams that represent three possible relationships between smoking, ESRD, and albumin-to-creatinine ratio (ACR) in the Study of Heart and Renal.

Pharmacokinetic behavior of mycophenolate mofetil (MMF) after oral administration (see text for details). Pharmacokinetic behavior of mycophenolate mofetil.

Distribution of SDS for serum creatinine, serum BUN, SBP, and DBP per quintiles of KS. Quintiles are expressed in SDS (see Figure 1B): 1st quintile,

A decision matrix for readers, reviewers, and guideline makers to conceptualize results-based and process-based merits in clinical trials. A decision matrix.

Effect of intervention differed across racial and socioeconomic groups

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

Bland-Altman plot of arterial and central venous blood Pco2 showing the regression line (solid line) and the 95% limits of agreement of −12.3 to 4.8 mmHg.

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Temporal distribution (from time 0 to 720 min after drug administration) of mean dosage-adjusted mycophenolic acid (MPA) concentrations at month 6 after.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Study protocol. Study protocol. All participants were studied on four occasions: Twice before and twice after an 8-wk treatment period on low-dosage, low.

Volume 77, Issue 2, Pages (January 2010)

Perception of indications for referral to a nephrologist among internal medicine residents according to the postgraduate year (PGY). Perception of indications.

Intersubject distribution of eGFR slope (left) and mGFR slope (right).

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Suggested treatment algorithm for resistant lupus nephritis Suggested treatment algorithm for resistant lupus nephritis.Resistant indicates 25% decline in estimated GFR or ESRD, 100% increase in urinary protein/urinary creatinine ratio, or the presence of an active urinary sediment. Suggested treatment algorithm for resistant lupus nephritis.Resistant indicates 25% decline in estimated GFR or ESRD, 100% increase in urinary protein/urinary creatinine ratio, or the presence of an active urinary sediment. LN, lupus nephritis; MMF, mycophenolate mofetil; NIH, National Institutes of Health; ELNT, Euro-Lupus Nephritis Trial; CYC, cyclophosphamide; CNI, calcineurin inhibitor. Sean Kalloo et al. CJASN 2013;8:154-161 ©2013 by American Society of Nephrology